Clinical Trial Update: Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1/1b dose-escalation study of BSI-201 as a single agent and in combination with Irinotecan in advanced solid tumors; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• BSI-201 (iniparib)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Sanofi | Conditions: Tumors | Phase 1 | Status: COMPLETED